How does HLS's PS Ratio compare to its peers?

HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (1.3x).

How does HLS's PS Ratio compare vs other companies in the AU Healthcare Industry?

HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the Oceanic Healthcare industry average (1.4x).

What is HLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLS is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

What is the Fair Price of HLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HLS (A$1.41) is trading below our estimate of [[fair value]] (A$1.57)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Healius (ASX:HLS) - Stock Price, News & Analysis

HLS Stock Overview

Provides specialty diagnostic services to consumer and practitioners in Australia. More details

HLS fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 10.2% below our estimate of its fair value

Earnings are forecast to grow 85.21% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been diluted in the past year

Healius Limited Competitors

Australian Clinical Labs

ASX:ACL

AU$689.5m

Integral Diagnostics

ASX:IDX

AU$666.7m

Capitol Health

ASX:CAJ

AU$378.5m

Healthia

ASX:HLA

AU$252.1m

Price History & Performance

Summary of all time highs, changes and price drops for Healius
Historical stock prices
Current Share Price	AU$1.41
52 Week High	AU$1.86
52 Week Low	AU$1.08
Beta	0.77
11 Month Change	-11.04%
3 Month Change	-16.81%
1 Year Change	-5.05%
33 Year Change	-70.32%
5 Year Change	-50.70%
Change since IPO	0.71%

Recent updates

Shareholder Returns

	HLS	AU Healthcare	AU Market
7D	-0.7%	4.0%	0.5%
1Y	-5.1%	10.3%	17.4%

Return vs Industry: HLS underperformed the Australian Healthcare industry which returned 10.3% over the past year.

Return vs Market: HLS underperformed the Australian Market which returned 17.4% over the past year.

Price Volatility

Is HLS's price volatile compared to industry and market?
HLS volatility
HLS Average Weekly Movement	6.9%
Healthcare Industry Average Movement	4.8%
Market Average Movement	8.3%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.2%

Stable Share Price: HLS has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: HLS's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1994	6,994	Paul Anderson	www.healius.com.au

Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services.

Healius Limited Fundamentals Summary

How do Healius's earnings and revenue compare to its market cap?
HLS fundamental statistics
Market cap	AU$1.02b
Earnings (TTM)	-AU$636.00m
Revenue (TTM)	AU$1.75b

0.6x

P/S Ratio

-1.6x

P/E Ratio

Is HLS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HLS income statement (TTM)
Revenue	AU$1.75b
Cost of Revenue	AU$1.21b
Gross Profit	AU$541.20m
Other Expenses	AU$1.18b
Earnings	-AU$636.00m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.88
Gross Margin	30.99%
Net Profit Margin	-36.42%
Debt/Equity Ratio	40.4%

How did HLS perform over the long term?

See historical performance and comparison

HLS Stock Overview

Rewards

Risk Analysis

Healius Limited Competitors

ASX:ACL

AU$689.5m

ASX:IDX

AU$666.7m

ASX:CAJ

AU$378.5m

ASX:HLA

AU$252.1m

Price History & Performance

Recent News & Updates

Healius Limited Announces Board Changes, Effective 1 December 2024

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Recent updates

Healius Limited Announces Board Changes, Effective 1 December 2024

Price target increased by 14% to AU$1.77

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Price target increased by 8.4% to AU$1.68

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Healius Limited, Annual General Meeting, Nov 15, 2024

Price target increased by 7.5% to AU$1.51

Full year 2024 earnings: Revenues exceed analyst expectations

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings: Revenues miss analyst expectations

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Consensus EPS estimates fall by 37%

Consensus EPS estimates fall by 37%

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

Consensus EPS estimates increase by 34%

Consensus EPS estimates increase by 36%

Consensus EPS estimates increase by 22%

High number of new directors

Consensus EPS estimates increase by 18%

Is Healius Limited (ASX:HLS) Trading At A 50% Discount?

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Consensus EPS estimates increase by 17%

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Consensus EPS estimates fall by 21%

At AU$3.07, Is It Time To Put Healius Limited (ASX:HLS) On Your Watch List?

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Consensus forecasts updated

Price target decreased to AU$3.23

Consensus EPS estimates fall by 13%

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

Here's Why Healius (ASX:HLS) Can Manage Its Debt Responsibly

Consensus EPS estimates fall by 27%

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Is Now An Opportune Moment To Examine Healius Limited (ASX:HLS)?

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock